ReviewMolecular biology reports2026
Integrated roles of miR-125b, miR-375, and miR-451 in breast cancer chemoresistance: mechanistic insights and translational implications.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Breast cancer is the most frequently diagnosed malignancy among women globally and the resistance to chemotherapy and targeted therapies remains a major hindrance to successful treatment. Emerging data suggests that microRNAs (miRNAs) play a critical role in controlling drug response by modulating cellular processes such as apoptosis, drug efflux, epithelial-mesenchymal transition (EMT), cancer stem cell (CSC) maintenance and survival signaling pathways. This narrative review aims to summaries the existing data about the involvement of three important miRNAs, miR-125b, miR-375 and miR-451 in breast cancer chemoresistance, based on the studies gathered from PubMed, Scopus and Web of Science up to December 2025. Current data indicates that miR-125b has a context-dependent dual role, mainly operating as a tumor suppressor during early carcinogenesis, but contributing to acquired chemoresistance under therapeutic pressure via regulating apoptosis-related genes and CSC-associated pathways. In contrast, the biological roles of miR-375 and miR-451 are highly dependent on breast cancer subtype. miR-375 is constitutively enriched in ER-positive luminal breast cancer, where its downregulation contributes to endocrine and anti-HER2 therapy resistance via dysregulation of the IGF1R, YAP1, JAK2/STAT3 and MTDH pathways, whereas its role in triple-negative breast cancer remains incompletely understood and may involve extracellular communication within the tumor microenvironment. Similarly, lower miR-451 expression induces MDR1/P-glycoprotein, Bcl-2 and YWHAZ signaling-mediated multidrug resistance, with differences in tissue and circulation levels underscoring the relevance of extracellular vesicle trafficking and preanalytical variables including hemolysis. These data collectively suggest the potential value of these miRNAs as biomarkers and therapeutic targets but also highlight the need for subtype-specific interpretation, standardized analytical methods, and further prospective clinical validation before clinical implementation.
Indexed as
Identifiers
42684565What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.